Plain-English translation of NCT06002659 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new type of cancer therapy made from your own immune cells. Doctors remove some of your T cells (a type of white blood cell), engineer them in the laboratory to recognize and attack lymphoma cells, and then infuse them back into your body. The goal is to help patients whose cancer has come back or stopped responding to other treatments.
Some patients with lymphoma don't respond to existing CAR-T cell therapies, and others relapse after initial success. This medication is designed to work differently by not only attacking cancer cells but also activating your body's natural immune system to prevent the cancer from escaping treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first undergo a procedure called leukapheresis, where doctors collect some of your white blood cells through a needle in your arm. These cells are sent to the laboratory to be engineered and grown. While you wait, you'll have regular clinic visits to monitor your health. Once your engineered cells are ready, you'll receive them back as an infusion. The trial will then carefully track your health, safety, and how well the treatment works through regular blood tests and scans.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Sweden
Phase
Safety & dosing / Early efficacy
Sponsor
Uppsala University
Collaborators
Elicera Therapeutics, Uppsala University Hospital
Enrollment target
~18 participants
Started
May 2024
Primary completion
December 2027
Last updated on clinicaltrials.gov in May 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gunilla Enblad, MD/PhD
Uppsala University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.